Next CERIC Seminar
October 24th CMM Lecture Hall (L8:00)
Speaker: Alexander Espinosa, Rheumatology Unit, Center for Molecular Medicine, Karolinska Institutet
Title: CRISPR/Cas9 - the next generation
Host: Marie-Wahren Herlenius
Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions
Anna Sala-Cunill, Jenny Björkqvist, Riccardo Senter, Mar Guilarte, Victoria Cardona, Moises Labrador, Katrin F. Nickel, Lynn Butler, Olga Luengo, Parvin Kumar, Linda Labberton, Andy Long, Antonio Di Gennaro, Ellinor Kenne, Anne Jämsä, Thorsten Krieger, Hartmut Schlüter, Tobias Fuchs, Stefanie Flohr, Ulrich Hassiepen, Frederic Cumin, Keith McCrae, Coen Maas, Evi Stavrou, and Thomas Renné. Journal of Allergy and Clinical Immunology pii: S0091-6749(14)01111-7. doi: 10.1016/j.jaci.2014.07.057
CERIC's goal is to be an internationally leading center in chronic inflammation, the pathological process that links inflammatory disorders such as multiple sclerosis, rheumatoid arthritis and psoriasis with atherosclerotic cardiovascular disease. For this purpose, we will build on existing, strong research in inflammatory mediators, autoimmunity , chronic inflammatory diseases, and cardiovascular disease at the Karolinska Institutet.
The following research aims will be addressed:
Aim 1: To determine why chronic inflammation sometimes, but not always, results in increased atherosclerosis and leads to myocardial infarction or stroke (cardiovascular disease).
Aim 2: To identify novel therapy targets and investigate the effects of targeted therapies against chronic inflammatory diseases and cardiovascualr diseases
Taken together, these two approaches will allow us to both understand the etiology and pathogenesis of chronic inflammatory diseases and cardiovascular disease and provide a basis for improved prevention and therapy for chronic inflammatory diseases and inflammatory cardiovascular disease, two major challenges to health in the population.